MK-2870-U01 Substudy 1: A Clinical Trial of Sacituzumab Tirumotecan to Treat Prostate Cancer (MK-2870-01A)
Metastatic Castration-resistant Prostate Cancer
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +1.9
5 insiders sold shares within a month
Since Aug 13, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 1/2
- Patients
- 290 (planned)
- Started
- Dec 14, 2026
- Main results expected
- Jun 29, 2032
- Fully finished
- Jun 29, 2032
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Efficacy Phase: Objective Response Rate (ORR)
Measured over: Up to approximately 66 months
Efficacy Phase: Number of Participants Who Experience at Least One Adverse Event (AE)
Measured over: Up to approximately 66 months
Efficacy Phase: Number of Participants Who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 66 months
Safety Lead-In (Combination Arms Only): Number of Participants Who Experience a Dose-Limiting Toxicity (DLT)
Measured over: Up to approximately 28 days
Safety Lead-In (Combination Arms Only): Number of Participants Who Experience at Least One AE
Measured over: Up to approximately 66 months
Safety Lead-In (Combination Arms Only): Number of Participants Who Discontinue Study Intervention Due to an AE
Measured over: Up to approximately 66 months
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 1.9, since 2026-08-13, fades (half-life)
Raw record changes
- none yet
Trial ID NCT07908524 · record last updated 2026-11-02 · checked 2026-11-09 15:47 UTC